Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects
NCT04515979 · MedPacto, Inc. · PHASE2 · terminated · last registry update 2024-12-09 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This is because Medpacto decided to modify its development strategy as the business and development environment changed.” | Open Targets' class: business administrative | Registry record, MedPacto, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TGFBR1 in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
No results, stops or Phase 3 starts on the same target in that window.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision